SYDNEY, Australia - October 16, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the appointment of Andrew Kay ...
SYDNEY--(BUSINESS WIRE)-- AdvanCell, a clinical-stage radiopharmaceutical company developing innovative cancer therapeutics, today announced the successful completion of an oversubscribed US$112 ...
SYDNEY--(BUSINESS WIRE)--AdvanCell, an Australian radiopharmaceutical company with a platform technology for a revolutionary cancer treatment called Targeted Alpha Therapy, announced today the closing ...
BRISBANE, Australia & BOSTON, February 02, 2026--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced ...
BRISBANE, Australia & INDIANAPOLIS--(BUSINESS WIRE)--AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapies, today announced an expansion to the scope and ...
AdvanCell and 48Hour Discovery Announce Collaboration and Exclusive Licensing Agreement to Develop a Lead-212 Alpha Radioligand Therapy Program EDMONTON, ALBERTA ...
Sydney, Australia – September 29, 2025 – AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, today announced that it will present six abstracts at ...
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 ...
The MarketWatch News Department was not involved in the creation of this content. BRISBANE, Australia & BOSTON--(BUSINESS WIRE)--February 02, 2026-- AdvanCell, a clinical-stage radiopharmaceutical ...
EDMONTON, ALBERTA, CANADA, February 2, 2026 /EINPresswire.com/ — AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha ...
AdvanCell Announces Collaboration and Exclusive Licensing Agreement with 48Hour Discovery to Develop a Novel Peptide-Based Lead-212 Radiotherapeutic for a Gastrointestinal Cancer with Significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results